Toripalimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | PD-1 |
| Clinical data | |
| Trade names | Loqtorzi |
| Other names | Toripalimab-tpzi |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a624004 |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Antineoplastic |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6548H10104N1728O2054S44 |
| Molar mass | 147309.54 g·mol−1 |
Toripalimab, sold under the brand name Loqtorzi, is a monoclonal antibody used for the treatment of melanoma and nasopharyngeal carcinoma.[3][7] Toripalimab is a recombinant humanized programmed cell death protein 1 (PD-1) monoclonal antibody that acts as a checkpoint inhibitor.[8]
In 2018, toripalimab was approved in China for the treatment of unresectable or metastatic melanoma that has failed previous systemic therapy.[8] In October 2023, the US Food and Drug Administration (FDA) approved toripalimab for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma when used with cisplatin and gemcitabine.[7][9]
- ^ "Tuoyi (AA-Med Pty Ltd)". Therapeutic Goods Administration (TGA). 19 February 2025. Retrieved 7 March 2025.
- ^ "Tuoyi toripalimab 240 mg/ 6 mL concentrated injection vial (426950)". Therapeutic Goods Administration (TGA). 22 January 2025. Retrieved 7 March 2025.
- ^ a b "Loqtorzi- toripalimab injection". DailyMed. 23 October 2023. Retrieved 20 November 2023.
- ^ "Loqtorzi- toripalimab-tpzi injection". DailyMed. 27 October 2023. Retrieved 20 November 2023.
- ^ Cite error: The named reference
Loqtorzi EPARwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Loqtorzi PIwas invoked but never defined (see the help page). - ^ a b "FDA approves toripalimab-tpzi for nasopharyngeal carcinoma". U.S. Food and Drug Administration (FDA). 27 October 2023. Archived from the original on 2 November 2023. Retrieved 2 November 2023. This article incorporates text from this source, which is in the public domain.
- ^ a b Keam SJ (April 2019). "Toripalimab: First Global Approval". Drugs. 79 (5): 573–578. doi:10.1007/s40265-019-01076-2. PMID 30805896. S2CID 71147241.
- ^ Li J, Zhang H, Zhu H, Li H (November 2023). "Clinical outcomes and immunological evaluation of toripalimab combination for cancer treatment: A systematic review and meta-analysis of randomized controlled trials". International Immunopharmacology. 125 (Pt B): 111176. doi:10.1016/j.intimp.2023.111176. PMID 37948860. S2CID 265121325.